● Recruiting

Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

Condition: Herpes Zoster (HZ) · Sponsor: Guangzhou Patronus Biotech Co., Ltd.

PhasePhase 1

Planned participants92

Who can joinAll sexes, 40 Years to no upper limit

Healthy volunteersYes

About this study

This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.

This description comes directly from the study's public registry record.

Talk to the study team

Renfeng Fan · 8613560231815 · gdsjkzx_sws_sps@gd.gov.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Guangdong Provincial Center for Disease Control and Prevention

Meizhou, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06874842